Xenon Pharmaceuticals (XENE) investor relations material

Clinical development and regulatory progress

• Azetukalner showed the largest median percentage change in seizure frequency in a registration study for focal onset seizures, with consistent efficacy and safety across pivotal trials, and NDA submission planned for Q3.

• The drug's potassium channel modulation offers a novel mechanism compared to existing sodium channel blockers and SV2A inhibitors, with positive feedback from key opinion leaders.

• Regulatory interactions with the FDA have been productive, with most NDA components prepared ahead of data readout; standard review is expected, with a 12-month timeline post-submission.

• Long-term data show sustained and increasing seizure freedom, with up to 40% of patients achieving at least 12 months of seizure reduction over four years.

• Ongoing X-TOLE3 phase III trial is designed to support ex-U.S. regulatory submissions, with enrollment completion expected later this year.

Competitive positioning and commercial strategy

• Azetukalner is the only Kv7 modulator with pivotal data in epilepsy, offering a robust dataset and temporal lead over competitors.

• Four dosage strengths are planned for the label, supporting individualized treatment and balancing efficacy with tolerability.

• The drug's ease of use, lack of titration, and favorable safety profile are expected to drive adoption among both epileptologists and general neurologists.

• Initial commercial focus will target 2,400 epileptologists and a subset of 18,000 general neurologists, with a starting sales force of about 75 reps and 12 MSLs.

• Commercial launch is expected to be gradual, with a goal to outperform prior branded ASM launches, leveraging strong data and experienced commercial leadership.

Market opportunity and pricing

• The U.S. focal onset seizure market includes about 1.9 million patients, with roughly half not well controlled and representing the primary target population.

• The market is highly genericized, with only one branded sodium channel blocker remaining; payer mix is about 40% commercial, with the rest split between Medicaid and Medicare.

• Branded agents typically face manageable reimbursement hurdles, and payer education is underway to support launch.

• There is potential for premium pricing above current branded agents, justified by efficacy, safety, and novel mechanism.

• International commercialization will likely rely on partnerships, with U.S. pricing and returns expected to drive the majority of economic value.